Trial Profile
A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms MENDEL-2; PROFICIO
- Sponsors Amgen
- 17 Aug 2018 Results (n=3146) of pooled analysis of this and other three trials (LAPLACE-2, RUTHERFORD-2, GAUSS-2) published in the Clinical Cardiology.
- 01 Mar 2017 Results (n=6026) of pooled safety analysis of this and other eleven trials (LAPLACE-TIMI 57,RUTHERFORD,GAUSS,MENDEL,YUKAWA,LAPLACE-2,RUTHERFORD-2,GAUSS-2,MENDEL-2,DISCARTES,THOMAS-1,THOMAS-2) published in the Circulation.
- 02 Sep 2015 Results (n=3146) of pooled analysis of this and other three trials (LAPLACE-2, RUTHERFORD-2, GAUSS-2) presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology